Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
Authors
Keywords
-
Journal
BLOOD
Volume 125, Issue 1, Pages 22-32
Publisher
American Society of Hematology
Online
2014-12-12
DOI
10.1182/blood-2014-05-577189
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.
- (2017) J. D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial.
- (2017) S. Le Gouill et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study
- (2015) Grzegorz S. Nowakowski et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of body mass index in survival outcome for lymphoma patients: US intergroup experience
- (2014) F. Hong et al. ANNALS OF ONCOLOGY
- Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes
- (2014) N. Chambwe et al. BLOOD
- Advances in the treatment of hematologic malignancies using immunoconjugates
- (2014) M. C. Palanca-Wessels et al. BLOOD
- Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
- (2014) D. W. Scott et al. BLOOD
- Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
- (2014) A. M. Petrich et al. BLOOD
- Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
- (2014) Sally F. Barrington et al. JOURNAL OF CLINICAL ONCOLOGY
- Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
- (2014) Matthew J. Maurer et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma
- (2014) Gerhard Held et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
- (2014) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
- (2014) Umberto Vitolo et al. LANCET ONCOLOGY
- Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma
- (2014) Luis F. Porrata et al. LEUKEMIA & LYMPHOMA
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
- (2013) Z. Zhou et al. BLOOD
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- The genetic basis of diffuse large B-cell lymphoma
- (2013) Laura Pasqualucci CURRENT OPINION IN HEMATOLOGY
- Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
- (2013) N. Mounier et al. HAEMATOLOGICA
- Patterns of Failure in Advanced Stage Diffuse Large B-Cell Lymphoma Patients After Complete Response to R-CHOP Immunochemotherapy and the Emerging Role of Consolidative Radiation Therapy
- (2013) Zheng Shi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
- (2013) Marieta Caganova et al. JOURNAL OF CLINICAL INVESTIGATION
- Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2013) Ken Ohmachi et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
- (2013) David Cunningham et al. LANCET
- Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
- (2013) Richard Delarue et al. LANCET ONCOLOGY
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Diffuse large B-cell lymphoma—treatment approaches in the molecular era
- (2013) Mark Roschewski et al. Nature Reviews Clinical Oncology
- Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
- (2013) Patrick J. Stiff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic heterogeneity of diffuse large B-cell lymphoma
- (2013) Jenny Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
- (2013) M. Pfeifer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP
- (2013) L. Cerchietti et al. Hematology-American Society of Hematology Education Program
- Pathogenesis of Human B Cell Lymphomas
- (2012) Arthur L. Shaffer et al. Annual Review of Immunology
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
- (2012) C. Muller et al. BLOOD
- MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
- (2012) W. Cuccuini et al. BLOOD
- Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy
- (2012) Belinda A. Campbell et al. CANCER
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
- (2012) Yibin Yang et al. CANCER CELL
- Chemotherapy Alone for Localized Diffuse Large B-Cell Lymphoma
- (2012) Laurie H. Sehn CANCER JOURNAL
- Impact of Consolidation Radiation Therapy in Stage III-IV Diffuse Large B-cell Lymphoma With Negative Post-Chemotherapy Radiologic Imaging
- (2012) Jennifer A. Dorth et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Double-Hit Diffuse Large B-Cell Lymphoma
- (2012) Jonathan W. Friedberg JOURNAL OF CLINICAL ONCOLOGY
- Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell Lymphoma
- (2012) Kenneth R. Carson et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Tina Marie Green et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Nathalie A. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
- (2012) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
- (2012) Norbert Schmitz et al. LANCET ONCOLOGY
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
- (2012) J. G. Lohr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group
- (2011) A. O. Gang et al. ANNALS OF ONCOLOGY
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
- (2011) T. E. Witzig et al. ANNALS OF ONCOLOGY
- Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype
- (2011) Francisco J. Hernandez-Ilizaliturri et al. CANCER
- Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
- (2011) Madhavi Challa-Malladi et al. CANCER CELL
- BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
- (2011) J. Iqbal et al. CLINICAL CANCER RESEARCH
- A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
- (2011) W. H. Wilson et al. HAEMATOLOGICA
- Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma
- (2011) Matthew J. Maurer et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
- (2011) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
- (2011) Catherine Thieblemont et al. JOURNAL OF CLINICAL ONCOLOGY
- Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
- (2011) Christian Récher et al. LANCET
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
- (2011) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
- (2011) G S Nowakowski et al. LEUKEMIA
- The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma
- (2011) R A Wilcox et al. LEUKEMIA
- Inactivating mutations of acetyltransferase genes in B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
- (2011) Ryan D. Morin et al. NATURE
- Analysis of the coding genome of diffuse large B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE GENETICS
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
- (2010) Leandro C. Cerchietti et al. CANCER CELL
- Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
- (2010) Sharon Barrans et al. JOURNAL OF CLINICAL ONCOLOGY
- Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma
- (2010) Matthew T. Drake et al. JOURNAL OF CLINICAL ONCOLOGY
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Chemotherapy
- (2010) Jack Phan et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era
- (2010) Marita Ziepert et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
- (2010) Paul N. Meyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Aggressive Lymphomas
- (2010) Georg Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
- (2009) K. Dunleavy et al. BLOOD
- MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
- (2009) K. J. Savage et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
- Frequent inactivation of A20 in B-cell lymphomas
- (2009) Motohiro Kato et al. NATURE
- Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
- (2008) L. M. Rimsza et al. BLOOD
- Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
- (2008) Wyndham H. Wilson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma
- (2008) Maria Christina Cox et al. LEUKEMIA & LYMPHOMA
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
- (2008) G. Lenz et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started